Research programme: cell-based therapeutics - MaxCyte

Drug Profile

Research programme: cell-based therapeutics - MaxCyte

Alternative Names: CAR therapy - MaxCyte; Chimeric Antigen Receptor T cell therapy - MaxCyte; Gene modified autologous cell therapies - Maxcyte; MaxCyte GT™

Latest Information Update: 15 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MaxCyte
  • Developer Johns Hopkins University; MaxCyte
  • Class CAR-T cell therapies; Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lymphoma; Solid tumours
  • Discontinued Metabolic disorders; Rheumatoid arthritis

Most Recent Events

  • 23 Apr 2015 MaxCyte and John Hopkins University agree to co-develop Chimeric Antigen Receptor T cell therapy for Solid tumours
  • 07 Mar 2011 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)
  • 07 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top